Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Merrimack Pharmaceuticals, Inc. (MACK) Finishes Patient Enrollment in Phase 2 Study of MM-121

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing, and preparing to commercialize innovative drugs paired with companion diagnostics for the treatment of cancer. The company currently has six targeted therapeutic oncology candidates in clinical development.

The company announced today that the last patient has been enrolled in the second cohort of a randomized, three-cohort Phase II clinical trial of its MM-121 drug candidate in combination with erlotinib for the treatment of non-small cell lung cancer patients. MM-121 has been developed together with Sanofi since 2009 and is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival.

This particular cohort – Group A – focuses on 133 patients with EGFR wild-type tumors and is part of the overall Phase II that focuses on three separate population of patients. This cohort was designed to see if MM-121 in combination with erlotinib is more effective than treatment with erlotinib alone. The patients in this group have the EGFR wild-type tumors with recurring or progressive disease following at least one chemotherapy-containing regimen and have not received prior EGFR tyrosine kinase inhibitor therapy. Results from this group are expected to be reported in the second half of 2013.

The second cohort – Group B – includes patients whose tumors contain an EGFR mutation and have not received prior EGFR tyrosine kinase inhibitor treatment. Enrollment for Group B is ongoing. The third cohort – Group C – includes patients that were previously treated with an EGFR tyrosine kinase inhibitor and progressed on that therapy. Results for this group were reported in April 2013.

For additional information about Merrimack Pharmaceuticals and its oncology drug candidates, including MM-121, please visit www.merrimackpharma.com

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *